GENETICALLY MODIFIED ENDOC-βH5®
Stable & Transient Transfection
APPLICATIONS
The ADAPT® platform enables both stable and transient gene modification of EndoC-βH5®. offering a unique tool to validate your target gene in a native-like human beta cell. These fully customized, genetically modified EndoC-βH5® cells are specifically designed for assay development and screening campaigns.
KEY ADVANTAGES
GENETICALLY MODIFIED HUMAN BETA CELL
STABILITY OVER YEARS
EndoC-βH5® CELL LINE OF REFERENCE
Knock-in
Transgenesis / Stable transgene overexpression
Knock-down
Lentiviral sh/si/miRNA
Knock-out
Crispr-KO
Gene expression
Reporter gene
WHY ADAPT®?
A unique strategy for designing genome edited human beta cell lines
ADAPT® TRACK RECORD
Type 1 and Type 2 Diabetes Modeling
Two functional models have been successfully created through this platform: HLA-A2 EndoC-βH5® and GLTx EndoC-βH5®. From these two pathophysiological models, associated assays have been developed to reveal drug potential: T-cell killing assay and Glucolipotoxicity-mediated Type 2 Diabetes Assay.
WHY CHOOSE HUMAN CELL DESIGN AS YOUR EXPERT PARTNER?
Contact us to discuss your project requirements and challenges and get your project started today!
DISCUSS YOUR NEEDS WITH OUR EXPERTS
– Solutions oriented to support your success
DESIGN YOUR PROJECT
Experimental plan tailored to your objectives
OPTIMIZE YOUR BUDGET, MINIMIZE YOUR RISKS
A step-by-step approach with GO / No GO
EXPLOIT YOUR RESULTS
Full data analysis, comprehensive report, and actionable insights
TRANSPARENCY
Real-time reporting & assigned project manager
